Background Research: RGD-Modified Smart Liposome Systems Break Through in Tumor Therapy

In 2025, Science Advances published a groundbreaking study revealing that PEGylated liposomes modified with RGD peptides significantly enhanced penetration and cellular uptake in tumor tissues. This system leverages pH-responsive mechanisms to enable highly precise, controlled drug release within the acidic tumor microenvironment—dramatically improving local drug retention and bioavailability.

This breakthrough marks a shift in liposomal drug delivery from passive accumulation to controllable, trigger-based precision delivery. Litchlab stands at the forefront of this transformation.

Litchlab: A Full-Spectrum Liposome Drug Delivery Platform for Targeted Therapeutics

As an innovation-driven company specializing in nanocarrier systems, Litchlab offers an end-to-end development solution for liposomal drugs—from formulation design → drug encapsulation → surface targeting → responsive mechanism engineering → IND translation → cGMP production.

Key Technical Strengths:

1️⃣ Targeted Ligand Conjugation System

• A diverse range of ligands: antibody fragments, aptamers, RGD peptides, tumor-homing peptides, glycan ligands

• Targeting key tumor biomarkers: PD-L1, HER2, αvβ3, EGFR, etc.

• Enhances tumor accumulation by 5–10× on average

• Utilizes efficient conjugation strategies: EDC/NHS, Click Chemistry, Maleimide-Thiol coupling

2️⃣ Microenvironment-Responsive Release Mechanisms

• pH-sensitive: triggers drug release in acidic tumor environments (pH 5.5–6.5)

• GSH-responsive: leverages elevated intracellular glutathione levels for intracellular release

• Enzyme-responsive: MMP-2/9-mediated degradation of the liposomal matrix

• Enables spatial and temporal control for maximizing therapeutic impact

3️⃣ Versatile Drug Loading Platforms

• Compatible with multiple production techniques: REV, thin-film dispersion, microfluidics

• High encapsulation efficiency (>85%), particle sizes 80–150 nm, PDI < 0.2

• Supports various payload types:

• Small molecules: Paclitaxel, Doxorubicin, Cisplatin

• Biologics: Interferons, monoclonal antibodies, proteases

• Nucleic acids: siRNA, mRNA, CRISPR components

• Radiopharmaceuticals: Lu-177, Zr-89, etc.

4️⃣ IND and CMC-Integrated Acceleration Services

• QbD-based process development and stability profiling

• Fully compliant with FDA/EMA/NMPA regulations (ICH Q8/Q11)

• Supports pilot to commercial-scale cGMP manufacturing, covering early clinical stages and tech transfer
  

  
  

Representative Applications:

Conclusion: Redefining Precision Liposomal Delivery through “Structural Design + Controlled Release”

Precision drug delivery is no longer a distant vision—it’s happening now. By advancing its core technology framework in targeting ligands, microenvironmental responsiveness, and multimodal payload integration, Litchlab is empowering global pharma and biotech partners to translate liposomal drugs into tangible breakthroughs in oncology, immunotherapy, gene modulation, and beyond.

For more information, please feel free to contact us at:  

E-Mail:RD2@Litchlab.com